Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Current ratio
Zoetis Inc.'s current ratio at the end of the quarter to 30 June 2026 was 3.1×, up 0.1× from fiscal 2025 (3.0×). Over the past ten years it has ranged from 1.8× (fiscal 2024) to 3.9× (fiscal 2021); the current reading is higher than 45% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.3× and in line with the Healthcare sector median of 3.0×.
Current ratio, annual
Annual
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.0× | 72.61% |
| FY2024 | 1.8× | (47.75%) |
| FY2023 | 3.4× | 41.68% |
| FY2022 | 2.4× | (38.54%) |
| FY2021 | 3.9× | 26.58% |
| FY2020 | 3.0× | 15.88% |
| FY2019 | 2.6× | (26.91%) |
| FY2018 | 3.6× | (6.69%) |
| FY2017 | 3.9× | 27.01% |
| FY2016 | 3.0× | 41.13% |
Quarterly
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.1× | (2.20%) |
| Mar 2026 | 3.2× | 1.17% |
| Dec 2025 | 3.1× | (14.44%) |
| Sep 2025 | 3.6× | 107.03% |
| 42 more quarters | Free account |
Against its own ten years
Low 1.8×
High 3.9×
Ten-year median
3.0×
Current reading's percentile
45
Current ratio against peers
| Company | Current ratio |
|---|---|
| UTHR United Therapeutics Corporation compare | 5.7× |
| ZTS Zoetis Inc. | 3.1× |
| ELAN Elanco Animal Health Incorporated compare | 2.1× |
| RDY Dr. Reddy's Laboratories Ltd compare | 1.9× |
| NBIX Neurocrine Biosciences, Inc. compare | 1.9× |
| VTRS Viatris Inc. compare | 1.6× |
| TAK Takeda Pharmaceutical Co. compare | 1.1× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 0.9× |
| HLN Haleon PLC Sponsored ADR compare | 0.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.3× |
| Healthcare sector median | 3.0× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement